Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Liabilities and Shareholders Equity (2019 - 2025)

Korro Bio's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $113.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 49.83% year-over-year to $113.5 million, compared with a TTM value of $657.7 million through Dec 2025, down 28.31%, and an annual FY2025 reading of $113.5 million, down 49.83% over the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $113.5 million at Korro Bio, down from $161.5 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $249.6 million in Q2 2024, with the low at $46.3 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $169.9 million, with a median of $182.9 million recorded in 2021.
  • Year-over-year, Liabilities and Shareholders Equity tumbled 65.92% in 2023 and then surged 425.45% in 2024.
  • Tracing KRRO's Liabilities and Shareholders Equity over 5 years: stood at $185.4 million in 2021, then crashed by 60.22% to $73.7 million in 2022, then surged by 200.59% to $221.7 million in 2023, then grew by 2.06% to $226.2 million in 2024, then crashed by 49.83% to $113.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Liabilities and Shareholders Equity are $113.5 million (Q4 2025), $161.5 million (Q3 2025), and $180.4 million (Q2 2025).